Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
NCT04932967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 91
Last updated 2022-06-22
Summary
This is a multicenter retrospective, non-interventional observational study to evaluate the efficacy of nMoAbs in HM patients.
Conditions
- Covid19
- Hematological Malignancy
Sponsors & Collaborators
-
Gruppo Italiano Malattie EMatologiche dell'Adulto
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-30
- Primary Completion
- 2022-04-11
- Completion
- 2022-04-11
Countries
- Italy
Study Locations
More Related Trials
-
Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies
NCT05612607 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
NCT07057778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Anti-CD38 Antibody Treating APS With Thrombocytopenia
NCT05983952 ·Status: RECRUITING ·Phase: PHASE2
-
SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications
NCT04539678 ·Status: COMPLETED
-
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
NCT05599880 ·Status: RECRUITING ·Phase: PHASE2
-
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
NCT07268898 ·Status: NOT_YET_RECRUITING
-
Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
NCT05852847 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
NCT02773290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
NCT05369377 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)
NCT01162941 ·Status: UNKNOWN ·Phase: PHASE2
-
Gut Microbiota in ITP
NCT05118126 ·Status: UNKNOWN
-
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
NCT05830916 ·Status: NOT_YET_RECRUITING
-
Anti-BCMA CAR T-Cell Therapy for R/R ITP
NCT05315778 ·Status: UNKNOWN ·Phase: PHASE2
-
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
NCT05678621 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
NCT05333861 ·Status: NOT_YET_RECRUITING
-
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391 ·Status: RECRUITING ·Phase: PHASE2
-
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
NCT04192916 ·Status: COMPLETED
-
Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP
NCT04735588 ·Status: UNKNOWN
-
Immune Thrombocytopenia Management in Adults
NCT05861297 ·Status: UNKNOWN ·Phase: PHASE4
-
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
NCT02094417 ·Status: COMPLETED ·Phase: PHASE2
-
Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy
NCT06476535 ·Status: ACTIVE_NOT_RECRUITING
-
The Serum Lipid Profiles in ITP: a Retrospective Study
NCT05095896 ·Status: COMPLETED
-
Phase III Study on HMPL-523 for Treatment of ITP
NCT05029635 ·Status: COMPLETED ·Phase: PHASE3
-
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
NCT02859909 ·Status: COMPLETED ·Phase: PHASE3